Cosentino F, Grant PJ, Aboyans V et al (2020) 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J 41(2):255–323

Article  PubMed  Google Scholar 

Dal Canto E, Ceriello A, Rydén L et al (2019) Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol 26(2_suppl):25–32

Article  Google Scholar 

Powell-Wiley TM, Poirier P, Burke LE et al (2021) Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 143(21):e984–e1010

Article  PubMed  PubMed Central  Google Scholar 

Lopez-Jimenez F, Almahmeed W, Bays H et al (2022) Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation. Eur J Prev Cardiol 29(17):2218–2237

Article  PubMed  Google Scholar 

Katta N, Loethen T, Lavie CJ, Alpert MA (2021) Obesity and coronary heart disease: epidemiology, pathology, and coronary artery imaging. Curr Probl Cardiol 46(3):100655

Article  PubMed  Google Scholar 

Sun H, Saeedi P, Karuranga S et al (2022) IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183:109119

Article  PubMed  Google Scholar 

Phelps NH, Singleton RK, Zhou B et al (2024) Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet 403(10431):1027–1050

Article  Google Scholar 

Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, Danaei G (2014) Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1·8 million participants. Lancet 383(9921):970–983

PubMed  Google Scholar 

Caleyachetty R, Thomas GN, Toulis KA et al (2017) Metabolically healthy obese and incident cardiovascular disease events among 3.5 million men and women. J Am Coll Cardiol 70(12):1429–1437

Article  PubMed  Google Scholar 

Sattar N, Lee MMY, Kristensen SL et al (2021) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 9(10):653–662

Article  CAS  PubMed  Google Scholar 

Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834–1844

Article  CAS  PubMed  Google Scholar 

Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311–322

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121–130

Article  CAS  PubMed  Google Scholar 

Wilding JP, Batterham RL, Calanna S et al (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384(11):989–1002

Article  CAS  PubMed  Google Scholar 

Davies M, Færch L, Jeppesen OK et al (2021) Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 397(10278):971–984

Article  CAS  PubMed  Google Scholar 

Wadden TA, Bailey TS, Billings LK et al (2021) Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 325(14):1403–1413

Article  CAS  PubMed  Google Scholar 

Rubino D, Abrahamsson N, Davies M et al (2021) Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 325(14):1414–1425

Article  CAS  PubMed  Google Scholar 

Garvey WT, Batterham RL, Bhatta M et al (2022) Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 28(10):2083–2091

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wadden TA, Hollander P, Klein S et al (2013) Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes (Lond) 37(11):1443–1451

Article  CAS  PubMed  Google Scholar 

Pi-Sunyer X, Astrup A, Fujioka K et al (2015) A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 373(1):11–22

Article  PubMed  Google Scholar 

Davies MJ, Bergenstal R, Bode B et al (2015) Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 314(7):687–699

Article  CAS  PubMed  Google Scholar 

Blackman A, Foster G, Zammit G et al (2016) Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial. Int J Obes (Lond) 40(8):1310–1319

Article  CAS  Google Scholar 

Jastreboff AM, Aronne LJ, Ahmad NN et al (2022) Tirzepatide once weekly for the treatment of obesity. N Engl J Med 387(3):205–216

Article  CAS  PubMed  Google Scholar 

Garvey WT, Frias JP, Jastreboff AM et al (2023) Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 402(10402):613–626

Article  CAS  PubMed  Google Scholar 

Wadden TA, Chao AM, Machineni S et al (2023) Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med 29(11):2909–2918

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aronne LJ, Sattar N, Horn DB et al (2024) Continued treatment with Tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 331(1):38–48

Article  CAS  PubMed  Google Scholar 

Lincoff AM, Brown-Frandsen K, Colhoun HM et al (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 389(24):2221–2232

Article  CAS  PubMed  Google Scholar 

Vrints C, Andreotti F, Koskinas KC et al (2024) 2024 ESC guidelines for the management of chronic coronary syndromes: developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 45(36):3415–3537

Article  CAS  PubMed  Google Scholar 

Marx N, Federici M, Schütt K et al (2023) 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J 44(39):4043–4140

Article  CAS  PubMed  Google Scholar 

Oettinger V, Hehn P, Bode C et al (2023) Center Volumes Correlate with Likelihood of Stent Implantation in German Coronary Angiography. J Interv Cardiol 2023:3723657

Article  PubMed  PubMed Central  Google Scholar 

Dornquast C, Kroll LE, Neuhauser HK, Willich SN, Reinhold T, Busch MA (2016) Regional differences in the prevalence of cardiovascular disease: results from the German health update (GEDA) from 2009–2012. Dtsch Arztebl Int 113(42):704

PubMed  PubMed Central  Google Scholar 

Stein MJ, Fischer B, Bohmann P et al (2024) Differences in anthropometric measures based on sex, age, and health status: findings from the german national cohort (NAKO). Dtsch Arztebl Int 121(7):207–213